See today's BioWorld Asia
To read the full story, subscribe or sign in.

Caliway’s CBL-514 meets endpoints in reducing abdominal fat

Dec. 17, 2024
By Tamra Sami
No Comments
Caliway Biopharmaceuticals’ lipolysis candidate, CBL-514, met all the primary and secondary efficacy endpoints in a phase IIb study for subcutaneous fat reduction, paving the way for the company to begin a global pivotal phase III study in 2025.
BioWorld BioWorld Asia Clinical Endocrine/metabolic Inflammatory Small molecule Asia-Pacific China FDA